GW Pharmaceuticals Plc (GWPH)

154.70
4.43 2.95
NASDAQ : Health Technology
Prev Close 150.27
Open 150.26
Day Low/High 150.17 / 155.36
52 Wk Low/High 92.65 / 151.98
Volume 475.34K
Avg Volume 398.80K
Exchange NASDAQ
Shares Outstanding 25.30M
Market Cap 3.74B
EPS -6.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cannabis Industry Sits on Precipice of Major Expansion

Cannabis Industry Sits on Precipice of Major Expansion

A string of good news for the cannabis sector may prompt institutional investors to get into the game, but watch valuations increase.

Not Thankful for Fridays: Cramer's 'Mad Money' Recap (Friday 4/20/18)

Not Thankful for Fridays: Cramer's 'Mad Money' Recap (Friday 4/20/18)

Jim Cramer says analysts and trade woes put a damper on buying ahead of the weekend. So let's get the game plan for next week.

The Market Is Finally Rewarding Stock Picking

The Market Is Finally Rewarding Stock Picking

The game plan is to spot the charts that have more room to run.

American Electric Power, Fifth Third Bancorp: 'Mad Money' Lightning Round

American Electric Power, Fifth Third Bancorp: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at American Electric Power, Fifth Third Bancorp, Applied Materials, EPR Properties, GW Pharmaceuticals and Longfin.

With Nothing to Buy, Everyone Sells: Cramer's 'Mad Money' Recap (Thur 3/22/18)

With Nothing to Buy, Everyone Sells: Cramer's 'Mad Money' Recap (Thur 3/22/18)

Jim Cramer calls it a tsunami of selling. Not one sector of the stock market got a break in Thursday's tariff-inspired decline.

GW Pharmaceuticals Announces The European Medicines Agency (EMA) Accepts Epidiolex® (cannabidiol) Marketing Authorization Application (MAA) For Review

GW Pharmaceuticals Announces The European Medicines Agency (EMA) Accepts Epidiolex® (cannabidiol) Marketing Authorization Application (MAA) For Review

MAA seeking regulatory approval of Epidiolex for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

Here Is the Buzz on My Under-the-Radar Top ETF Pick for 2018

Here Is the Buzz on My Under-the-Radar Top ETF Pick for 2018

Look for this name to jump quickly in popularity in 2018 as investors players search for a convenient way to play the marijuana niche.

California Cannabis Growers Celebrate New Year's Day as Weed Goes Legal

California Cannabis Growers Celebrate New Year's Day as Weed Goes Legal

Consumers in California eagerly await the end to it prohibition on the recreational use of cannabis.

GW Pharmaceuticals Reacquires Full Rights To Develop And Commercialize Sativex® In U.S.

GW Pharmaceuticals Reacquires Full Rights To Develop And Commercialize Sativex® In U.S.

- Previous License Agreement with Otsuka Terminated -

President Trump Looks Set for a Major Victory on Tax Reform: Market Recon

President Trump Looks Set for a Major Victory on Tax Reform: Market Recon

Party leaders will have to work toward merging the two versions of tax reform into one final bill.

Hold on for a Wild Ride: Cramer's 'Mad Money' Recap (Friday 12/1/17)

Hold on for a Wild Ride: Cramer's 'Mad Money' Recap (Friday 12/1/17)

From tax cuts to the Flynn fallout, Jim Cramer says investors have to be covered.

TheStreet Quant Rating: D (Sell)